Study protocol of the RAND-study: a multicenter, prospective cohort study investigating response and adherence to nilotinib treatment in chronic myeloid leukemia

BMC Cancer

Jacqueline G Hugtenburg³  Jeroen JWM Janssen²  Peter M van de Ven¹  Lonneke Timmers⁴  Eleonora L Swart⁴  Christel CLM Boons⁴ 

[1]Department of Epidemiology and Biostatistics, VU University Medical Center, De Boelelaan 1118, 1081 HV Amsterdam, The Netherlands

[2]Department of Hematology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands

[3]The EMGO Institute for Health and Care Research, VU University Medical Center, Van der Boechorststraat 7, 1081 BT Amsterdam, The Netherlands

[4]Department of Clinical Pharmacology and Pharmacy, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands

关键词: Patients’ experiences;    Medication adherence;    Response;    Treatment outcome;    Nilotinib;    Chronic myeloid leukemia;   

Others  :  858910
DOI  :  10.1186/1471-2407-14-247

 received in 2013-06-12, accepted in 2014-04-03,  发布年份 2014

【 摘 要 】

Background

The antitumor drug nilotinib has a large inter- and intra individual variability in pharmacokinetics. Adherence to treatment may substantially influence plasma levels and has been recognized as the most important determinant of treatment failure in chronic myeloid leukemia (CML). A better understanding of the various factors contributing to the efficacy of treatment is essential for the development of interventions to optimize the treatment of chronic phase CML (CP-CML) with a protein kinase inhibitor like nilotinib.

Methods/Design

In this multicenter prospective observational cohort study 70 adult patients with CP-CML starting treatment with nilotinib will be followed up for at least 12 months. Response to treatment is evaluated after 3, 6 and 12 months. Adherence is primarily assessed by counting the daily intake of nilotinib capsules by means of a medication event monitoring system (MEMS). Before the start of nilotinib treatment and after 3, 6 and 12 months, patients are asked to fill in a comprehensive questionnaire including topics on quality of life, side effects, attitude towards disease and medication, the patients’ appreciation of information received about the medication, and discontinuation, and trough plasma levels of nilotinib are measured.

Discussion

The present study aims to get more insight into the efficacy of treatment with nilotinib and the various aspects that govern optimal response, of which adherence is a primary endpoint. We hypothesize that patients who experience inadequate response levels to nilotinib are less adherent. In addition, their plasma levels of nilotinib may be lower. We expect that our findings will be useful for health care professionals to support patients with the use of nilotinib in order to derive optimal benefit from their medication.

Trial registration

Netherlands Trial Registry NTR3992.

【 授权许可】

   
2014 Boons et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Alvarez RH, Kantarjian H, Cortes JE: The biology of chronic myelogenous leukemia: implications for imatinib therapy. Semin Hematol 2007, 44:S4-S14.
• [2]Deininger M, O’Brien SG, Guilhot F, Goldman JM, Hochhaus H, Hughes TP, Radich JP, Hatfield AK, Mone M, Filian J, Reynolds J, Gathmann I, Larson RA, Druker BJ: International Randomized Study of Interferon Vs STI571 (IRIS) 8-year follow-up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009, 114:1126. (ASH Meeting): abstract
• [3]Tasigna: European Public Assessment Report - Product Information. Annex I - Summary of product characteristics 2013.
• [4]Gater A, Heron L, Betz-Webb L, Coombs J, Simmons J, Guilhot F, Rea D: Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia. Leuk Res 2012, 36:817-825.
• [5]Marin D, Bazeos A, Mahon F, Eliasson L, Milojkovic D, Bua M, Apperley J, Szydlo R, Desai R, Kozlowski K, Paliompeis C, Latham V, Foroni L, Molimard M, Reid A, Rezvani K, de Lavallade H, Guallar C, Goldman J, Khorashad J: Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010, 28:2381-2388.
• [6]Noens L, van Lierde MA, De Bock R, Verhoef G, Zachee P, Berneman Z, Martiat P, Mineur P, Van Eygen K, MacDonald K, De Geest S, Albrecht T, Abraham I: Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009, 113:5401-5411.
• [7]Jabbour EJ, Kantarjian H, Eliasson L, Cornelison AM, Marin D: Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Am J Hematol 2012, 87:687-691.
• [8]Eliasson L, Clifford S, Barber N, Marin D: Exploring chronic myeloid leukemia patients’ reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res 2011, 35:626-630.
• [9]Cornelison M, Jabbour EJ, Welch MA: Managing side effects of tyrosine kinase inhibitor therapy to optimize adherence in patients with chronic myeloid leukemia: the role of the midlevel practitioner. J Support Oncol 2012, 10:14-24.
• [10]Ossenkoppele GJ, Janssen JJWM, Posthuma EF, Falkenburg JHF, Bos GMJ, Petersen EJ, Schattenberg AV, Verhoef G, Vellenga E, Cornelissen JJ: Aanbevelingen voor de behandeling van chronische myeloïde leukemie 2011 [Guidelines for treatment of chronic myeloid leukemia 2011]. Ned Tijdschr Hematol 2011, 8:237-247.
• [11]Baccarani M, Pileri S, Steegmann JL, Muller M, Soverini S, Dreyling M: Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012, 23(7):vii72-vii77.
• [12]Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Shen Z, Mayer J, Pasquini R, Nakamae H, Huguet F, Boque C, Chuah C, Bleickardt E, Bradley-Garelik MB, Zhu C, Szatrowski T, Shapiro D, Baccarani M: Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010, 362:2260-2270.
• [13]Saglio G, Kim DW, Issaragrisil S, Le CP, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM: Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010, 362:2251-2259.
• [14]Jabbour E, Kantarjian HM, O’Brien S, Shan J, Quintas-Cardama A, Garcia-Manero G, Rios MB, Cortes JE: Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response? J Clin Oncol 2011, 29:4260-4265.
• [15]Cortes J, Hochhaus A, Hughes T, Kantarjian H: Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia. J Clin Oncol 2011, 29:524-531.
• [16]Giles FJ, Yin OQ, Sallas WM, le Coutre PD, Woodman RC, Ottmann OG, Baccarani M, Kantarjian HM: Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia. Eur J Clin Pharmacol 2013, 69:813-823.
• [17]Wilhelm AJ, Klijn A, den Burger JC, Visser OJ, Veldkamp AI, Janssen JJ, Swart EL: Clinical validation of dried blood spot sampling in therapeutic drug monitoring of ciclosporin A in allogeneic stem cell transplant recipients: direct comparison between capillary and venous sampling. Ther Drug Monit 2013, 35:92-95.
• [18]Wilhelm AJ, den Burger JC, Vos RM, Chahbouni A, Sinjewel A: Analysis of cyclosporin A in dried blood spots using liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877:1595-1598.
• [19]Larson RA, Yin OQ, Hochhaus A, Saglio G, Clark RE, Nakamae H, Gallagher NJ, Demirhan E, Hughes TP, Kantarjian HM, le Coutre PD: Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph + chronic myeloid leukemia in chronic phase. Eur J Clin Pharmacol 2011, 68:723-733.
• [20]Timmers L, Boons CCLM, Kropff F, van de Ven PM, Swart EL, Smit EF, Zweegman S, Kroep JR, Timmer-Bonte JN, Boven E, Hugtenburg JG: Adherence and patients’ experiences with the use of oral anticancer agents. Acta Oncol 2014, 53:259-267.
• [21]Butler JA, Peveler RC, Roderick P, Horne R, Mason JC: Measuring compliance with drug regimens after renal transplantation: comparison of self-report and clinician rating with electronic monitoring. Transplantation 2004, 77:786-789.
• [22]Horne R, Hankins M, Jenkins R: The Satisfaction with Information about Medicines Scale (SIMS): a new measurement tool for audit and research. Qual Health Care 2001, 10:135-140.
• [23]Aaronson NK, Muller M, Essink-Bot ML, Fekkes M, Sanderman R, te Velde A, Verrips E: Translation, Validation, and Norming of the Dutch Language Version of the SF-36 Health Survey in Community and Chronic Disease Populations. J Clin Epidemiol 1998, 51:1055-1068.
• [24]Hurst NP, Ruta DA, Kind P: Comparison of the MOS short form-12 (SF12) health status questionnaire with the SF36 in patients with rheumatoid arthritis. Br J Rheumatol 1998, 37:862-869.
• [25]Broadbent E, Petrie KJ, Main J, Weinman J: The brief illness perception questionnaire. J Psychosom Res 2006, 60:631-637.
• [26]Horne R, Weinman J, Hankins M: The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health 1999, 14:1-24.